Dermatological emergencies

Acknowledgements

Developed in collaboration with the University of Auckland Goodfellow Unit in 2007.

Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 2009.  

Images have been sourced from the following:

  • Hon Assoc Prof Amanda Oakley
  • The Department of Dermatology, Health Waikato
  • Prof Raimo Suhonen (Finland)
  • Arthur Ellis (medical artist)

 goodfellow unit logo

Drug eruptions CME

Next

Created 2008.

Learning objectives

Introduction

Drug eruptions are common – think carefully before you prescribe an unnecessary medicine! In hospital patients, rashes are commonly attributed to and often caused by medications. Clinical manifestations are very variable.

About 3% of patients admitted to hospital have rashes due to adverse drug reactions but in others the cutaneous signs are due to the underlying or intercurrent illness (e.g. viral or bacterial exanthemas or internal disease), non-specific reactions to treatment (e.g. sweat-rash due to prolonged bed rest with plastic sheeting) or independent skin disease that has not been recognised by hospital staff. True drug reactions may mimic other skin diseases. In general, the rash improves when the drug is withdrawn. This may occur quickly but in some cases takes weeks or longer.

Life-threatening features

Adverse drug eruptions can be dangerous, especially toxic epidermal necrolysis (TEN) and drug hypersensitivity syndrome.

Features indicating a potentially serious reaction include:

Mechanisms of cutaneous reactions to drugs

Immunological hypersensitivities
These represent true allergic reactions.
  • Type I anaphylactic reactions: anaphylaxis, anaphylactoid, urticaria, angioedema
  • Type II cytotoxic reactions: thrombocytopenia, TEN
  • Type III immune complex mediated reactions: serum sickness, vasculitis
  • Type IV cell mediated reactions: morbilliform rash, TEN
Non-immunological drug eruptions
These may be due to idiosyncratic reaction, hereditary enzyme deficiency, dose dependent cumulation, irritancy or toxicity. Examples include:
  • Eczema craquelé aggravated by diuretics
  • Cutaneous atrophy, striae and telangiectasia due to topical or systemic steroids
  • Drug-induced alopecia from cytotoxic medications
  • Erosions due to topically applied 5-fluorouracil
  • Cheilitis, xerosis and dermatitis due to lack of sebum on retinoids
  • Lithium-induced psoriasis (mechanism unknown)
  • Psoriasis aggravated by Interleukin II, which induces pro-inflammatory cytokines
  • Pigmentation due to accumulation of amiodarone within skin

History

The patient may need to be coaxed to report their drug history. Although adverse reactions are less likely to arise from drugs that the patient has been on for a long period of time, this is not always the case. Suggest these are brought to the clinic for inspection.

Ask about all medications taken in the last three months:

It is not possible to memorise all possible causes of all possible drug eruptions. Standard reference handbooks such as the MIMS and manufacturers' data sheets include rash in the list of potential adverse effects for nearly every drug.

Exanthematous drug reactions

These are often also described as toxic erythema. Features include:

The suspected drug or drugs should be discontinued, and the rash usually subsides within a week. Unfortunately there are no useful in vitro or in vivo tests to confirm hypersensitivity reactions and re-challenge is not recommended (although it sometimes occurs inadvertently at a later date). May cross-react with other drugs in the same class. Sometimes the rash clears despite continuing the responsible drug or re-challenge is tolerated without adverse reaction.

Drugs that cause exanthematous rashes in >1%
  • Penicillins
  • Carbamazepine
  • Allopurinol
  • Gold
  • Sulphonamides
  • NSAIDS
  • Phenytoin
  • Isoniazid
  • Chloramphenicol
  • Erythromycin
  • Streptomycin

Drug hypersensitivity syndrome

A morbilliform eruption in association with internal organ involvement and fever indicates possible drug hypersensitivity syndrome (DHS). This has a mortality rate of about 10%.

Drug-induced urticaria

Drug-induced urticaria may occur with or without angioedema. It arises up to three weeks after first exposure (or minutes on re-challenge). It may be due to type 1 hypersensitivity (e.g. penicillin), sometimes in association with anaphylaxis and constitutional symptoms (respiratory distress, vascular collapse and shock).

It may also be due to direct release of inflammatory mediators from mast cells on first exposure to the drug (e.g. opiates, aspirin, NSAID, muscle relaxants).

ACE inhibitors such as captopril and enalapril may cause recurrent angioedema without urticaria, rarely commencing months or years after the drug was first prescribed.

Serum sickness is combination of urticaria, fever and arthralgia (sometimes lymphadenopathy, nephritis, endocarditis) and may be due to antibiotics especially cefaclor.

Drugs that cause urticaria in >1%
  • Penicillins
  • Cephalosporins
  • Sulphonamides
  • Cytostatic agents
  • ACE inhibitors
  • Calcium channel blockers

Fixed drug eruption

Fixed drug eruption (FDE) refers to solitary or multiple oval plaques that arise over a few hours and may have central blisters. It frequently affects mucosal surfaces such as the genitals and lips. FDE resolves in a few days leaving purplish hyperpigmentation, then re-erupts in the same site on re-exposure to the causative drug, which is usually a medication taken intermittently such as paracetamol or antibiotics but may also be a food dye.

Purpura

Drug-related bleeding into the skin includes:

Drug-induced photosensitivity

Photosensitivity may be due to toxic or immunological mechanisms or both, from systemic or topical exposure to the medication. The rash affects sites of light exposure (UVA), but may spare habitually exposed areas such as the face and hands. Phototoxic reactions will affect everyone if the dose is high enough, and appears like sunburn (e.g. doxycycline, chlorpromazine). Photoallergic eruptions are generally eczematous or lichenoid (e.g. quinine).

Onycholysis may be due to drug-induced photosensitivity.

Drug-induced pigmentation

Several drugs may slowly induce hyperpigmentation of the skin and mucosal surfaces, due to the deposition of melanin (e.g. ACTH, oestrogen/progesterone, phenytoin), haemosiderin (minocycline), exogenous pigment (minocycline) or unknown mechanisms,

Other patterns of cutaneous reaction to drugs

Investigations

Adverse reactions to drugs are recognised by being suspicious of them; tests are rarely helpful. However eosinophilia in blood or tissue may be supportive.

Drugs can produce almost any histologic pattern and may appear identical to non-drug induced disorders.

Management

If suspicious of a drug eruption, stop the responsible drug and avoid new ones (especially in the same pharmacological class).

Treat the patient:

Activity

Describe the presentation and management of Drug Hypersensitivity Syndrome

Related information

Next

Email Newsletter

Would you like to receive our dermatology updates by email?

SIGN UP

Submit your images

We're seeking high-quality photos of skin diseases.  

SUBMIT A PHOTO

Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter